Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 312 participants.

Also called NCT04666298

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 312 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04666298
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04666298. Randomized; quadruple masking; primary purpose treatment. Start 2021-01-29 (actual); primary completion 2022-04-18 (actual). Results posted on 2023-05-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C
Acronym
ORION-15
Condition
Hypercholesterolemia
Condition
Heterozygous Familial Hypercholesterolemia
Intervention (Drug)
Inclisiran sodium
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct04666298
Content hash
dcaa69c03b1d7c13376c62e17ac3bab51ea6033dd3fa666835dab9c1e1b9fa81